Aldoxorubicin

1361644-26-9

C37H42N4O13

DMSO : 75 mg/mL (99.90 mM; Need ultrasonic)

Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related

Aldoxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin, which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models. IC50 & Target: Topoisomerase II^[4] In Vitro: Aldoxorubicin (INNO-206) (0.27 to 2.16 uM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion^[1]. In Vivo: Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGkappa-1A tumor^[1]. Aldoxorubicin (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study^[2]. Aldoxorubicin (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models^[3].